ASX Share rice
Tue 04 Aug 2020 - 06:09:am (Sydney)

COH Share Price

COCHLEAR LIMITEDCOHHealth Care Equipment & Services

COH Company Information

Name:

Cochlear Limited

Sector:

Healthcare

Industry:

Medical Devices

GIC Industry:

Health Care Equipment & Supplies

GIC Sub Industry:

Health Care Equipment

Address:

1 University Avenue Sydney NSW Australia 2109

Phone:

61 2 9428 6555

Full Time Employees:

4000

CEO, MD, Pres & Exec. Director:

Mr. Diggory William Howitt BE (Hons), MBA

Chief Financial Officer:

Mr. Brent Andrew Cubis B.Com., C.A., BComm, CA

Chief Technology Officer:

Mr. Jan Janssen

Pres of EMEA & Latin American Region:

Mr. Richard Brook

Pres of Americas Region:

Mr. Anthony Manna

Company Overview:

Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories. It also provides Cochlear true wireless devices comprising mini microphones, phone clips, and TV streamers; and Cochlear Vistafix bone-anchored facial prosthetic solutions to enhance the attachment and cosmetic outcome of facial prostheses. The company has strategic collaboration with GN Hearing to develop integrated hearing solutions. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

COH Share Price Information

Shares Issued:

65.69M

Market Capitalisation:

$13.06B

Dividend per Share:

$3.35

Ex Dividend Date:

2020-03-24

Dividend Yield:

1.68%

Revenue (TTM):

$1.48B

Revenue Per Share (TTM):

$25.60

Earnings per Share:

$5.294

Profit Margin:

0.2068

Operating Margin (TTM):

$0.24

Return On Assets (TTM):

$0.15

Return On Equity (TTM):

$0.42

Quarterly Revenue Growth (YOY):

0.074

Gross Profit(TTM):

$1.08B

Diluted Earnings Per Share (TTM):

$5.294

QuarterlyEarnings Growth(YOY):

0.224

COH CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-137,800,000

Change To Liabilities:

$29.10M

Total Cashflow From Investing Activities:

$-137,800,000

Net Borrowings:

$33.50M

Net Income:

$276.70M

Total Cash From Operating Activities:

$296M

Dividends Paid:

$-181,800,000

Capital Expenditures:

$114.60M

COH Income Statement

Income Date:

2019-06-30

Income Before Tax:

$365.60M

Net Income:

$276.70M

Gross Profit:

$1.08B

Operating Income:

$345.50M

Other Operating Expenses:

$-7,400,000

Interest Expense:

$5.20M

Income Tax Expense:

$88.90M

Total Revenue:

$1.43B

Total Operating Expenses:

$730.10M

Cost Of Revenue:

$351.10M

COH Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$155.60M

Total Liabilities:

$653.30M

Total Stockholder Equity:

$725.90M

Total Assets:

$1.38B

Common Stock:

$182.30M

Retained Earnings:

$558.90M

Other Liabilities:

$115.50M

Good Will:

$268.80M

Other Assets:

$155.90M

Cash:

$78.60M

Total Current Liabilities:

$359.50M

Short-Term Debt:

$3.30M

Property - Plant & Equipment:

$166.50M

Net Tangible Assets:

$351.90M

Long-Term Investments:

$47.80M

Total Current Assets:

$635M

Long-Term Debt:

$178.30M

Net Receivables:

$313.40M

Short-Term Investments:

$744.20M

Inventory:

$195.40M

Accounts Payable:

$160.80M

Non Currrent Assets (Other):

$744.20M

Short-Term Investments:

$744.20

Non Current Liabilities Total:

$293.80M

COH Share Price History

COH News

22 Jul, 2020
Australian shares closed lower on Wednesday, dragged down by the healthcare sector, as a record surge in COVID-19 cases in the country dented investor sentiment. Australia recorded 501 new coronavirus infections in the past 24 hours, its highest since the epidemic took hold in March, with Victoria state, of which Melbourne is the capital, accounting for almost 97% of the new cases. "The fact that metro Melbourne, which is about 5 million people, has already been in a lockdown for the last couple of weeks and still not seeing a drop in cases is probably something to be a little concerned about," said Steven Daghlian, market analyst at CommSec.
16 Jul, 2020
With a price-to-earnings (or "P/E") ratio of 36x Cochlear Limited (ASX:COH) may be sending very bearish signals at the...
06 Jul, 2020
Cochlear Limited (ASX:COH), the global leader in implantable hearing solutions, today announced the U.S. Food and Drug Administration (FDA) approval of three new products to its suite of hearing technology solutions. The approval of the Cochlear™ Nucleus® Kanso® 2 Sound Processor, Nucleus® 7 Sound Processor for Nucleus 22 Implant recipients and Custom Sound® Pro fitting software reflects Cochlear's ongoing commitment to innovation in hearing technology, providing access to smartphone connectivity and helping to improve hearing performance, and enhancing the cochlear implant fitting experience for hearing health professionals.
16 Jun, 2020
Cochlear's's (ASX:COH) stock is up by a considerable 13% over the past three months. Given the company's impressive...
19 May, 2020
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval on March 17 to lower the age of cochlear implantation from 12 months to 9 months for children with bilateral, profound sensorineural hearing loss. This important approval ensures children born deaf have earlier access to a cochlear implant which can provide them with the hearing capabilities to develop speech and language at a trajectory similar to their hearing peers. Ensuring children have access to sound as early as possible should be prioritized as surgeries begin resuming across the country due to the COVID-19 pandemic.
07 Apr, 2020
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval on April 2 for its Remote Check solution. This approval is the first step in commercializing the product offering, which is anticipated by the end of 2020. Cochlear will immediately begin a controlled market release of Remote Check in the U.S. and Canada by partnering with hearing healthcare providers and hospitals to quickly reach those most in need of audiological care during the COVID-19 pandemic, which supports social distancing by providing an alternative to in-person appointments.
26 Mar, 2020
Asia's equity capital market (ECM) bankers are pinning hopes on a pick-up in follow-on share sales when markets stabilise, after suffering the worst start to the year since the early days of the global financial crisis. Companies in the Asia-Pacific region have raised less through share sales this year than at any time since 2008 as stock market turmoil brought about by the coronavirus outbreak pushed investors and those seeking funds to the sidelines. In the first quarter, $20.28 billion was raised across the region including Japan, showed Refinitiv data, as markets experienced their most volatile days in decades.
19 Mar, 2020
Cochlear Limited (ASX:COH) is about to trade ex-dividend in the next 4 days. This means that investors who purchase...
12 Mar, 2020
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
10 Mar, 2020
Half Year 2020 Cochlear Ltd Earnings Presentation
18 Feb, 2020
Today we'll look at Cochlear Limited (ASX:COH) and reflect on its potential as an investment. In particular, we'll...
27 Jan, 2020
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today the winners of the 18th annual Graeme Clark and the ninth annual Anders Tjellström scholarships. The scholarships, named after two pioneers of the hearing implant industry, recognize Cochlear™ Nucleus® Implant and Baha® System recipients in the United States and Canada who uphold the Cochlear ideals of leadership, humanity, and demonstrate high academic achievement, to enable recipients to further accomplish their goals through education.
24 Jan, 2020
After reading Cochlear Limited's (ASX:COH) most recent earnings announcement (30 June 2019), I found it useful to look...
02 Jan, 2020
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it...
11 Dec, 2019
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announces today the U.S. Food and Drug Administration (FDA) clearance of the new Cochlear™ Osia® 2 System. The Osia System is the world's first active osseointegrated steady-state implant (OSI), a new category of bone conduction hearing solutions that uses digital piezoelectric stimulation to bypass damaged areas of the natural hearing system to send sound vibrations directly to the inner ear (cochlea).
09 Dec, 2019
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
13 Nov, 2019
Today we will run through one way of estimating the intrinsic value of Cochlear Limited (ASX:COH) by projecting its...
05 Nov, 2019
Gary started feeling frustrated and angry about not being able to fully participate in everyday life because of his hearing loss. Carol wasn't sure if Gary was losing his hearing or whether he was ignoring her at first. Gary's hearing loss started to progress, and he would get stronger and stronger hearing aids, but they were no longer helping him hear.
23 Oct, 2019
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

COH Dividend Payments

EX-Date Dividend Amount
2010-02-21$0.9500
2010-08-27$1.0500
2011-02-20$1.0500
2011-08-26$1.2000
2012-02-21$1.2000
2012-08-24$1.2500
2013-02-20$1.2500
2013-08-23$1.2700
2014-02-27$1.2700
2014-09-02$1.2700
2015-03-02$0.9000
2015-09-08$1.0000
2016-03-09$1.1000
2016-09-07$1.2000
2017-03-14$1.3000
2017-09-19$1.4000
2018-03-18$1.4000
2018-09-17$1.6000
2019-03-24$1.5500
2019-09-19$1.7500
2020-03-23$1.6000

COH Dividends (last 11 Years)